Friday, Nov 20, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Business | Hyderabad Based Dr Reddys Not To Sell Novo Nordisks Ozempic Like Drug In India

Hyderabad-based Dr Reddy’s not to sell Novo Nordisk’s Ozempic-like drug in India

The undertaking to Delhi HC follows a patent infringement plea filed by the Danish drugmaker against Dr Reddy’s Laboratories and OneSource Speciality Pharma. Novo Nordisk’s blockbuster weight-loss drug Ozempic Wegovy is expected to be launched soon in India

By IANS
Updated On - 31 May 2025, 05:51 PM
Hyderabad-based Dr Reddy’s not to sell Novo Nordisk’s Ozempic-like drug in India
whatsapp facebook twitter telegram

New Delhi: Ahead of the much-anticipated launch of Novo Nordisk’s blockbuster weight-loss drug Ozempic Wegovy in India, Dr Reddy’s has in an undertaking told the Delhi High Court it will not sell Danish drugmaker’s Ozempic-like drug in India.

The undertaking follows a patent infringement plea filed by the Danish drugmaker against Dr Reddy’s Laboratories and OneSource Speciality Pharma, earlier this week.

Also Read

  • Battle Of The Bulge: Are semaglutides the answer?

The advocates representing the Indian companies informed the court that they were granted a licence to manufacture semaglutide in December 2024 and have thus begun manufacturing it in April 2025.

While confirming they do not have a licence to sell the drug in India, the companies noted that they reserved the right to export it to countries where Novo Nordisk does not hold a patent. However, Novo Nordisk objected to the proposed export of the drug.

The two companies have engaged in a legal battle over semaglutide — the active ingredient in Wegovy and Ozempic. The popular obesity and diabetes drugs work by reducing appetite and slowing down the movement of food in the body.

Novo Nordisk has alleged that Dr Reddy’s and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export formulations.

Novo Nordisk’s counsel submitted that exporting an infringing product also amounts to patent infringement under the Patents Act, of 1970.

On the other hand, Dr Reddy’s contended that semaglutide was already disclosed in Novo Nordisk’s earlier Indian patent.

The Hyderabad-based drugmaker also accused Novo Nordisk of attempting to extend its monopoly by way of evergreening — a strategy where patent holders make minor modifications to existing products or processes to extend their market exclusivity.

The court has listed the matter for hearing on August 19.

Join Our Whatsapp Channel
  • Follow Us :
As preferred source
  • Tags
  • Business News
  • Delhi High Court
  • Dr Reddy's Laboratories (DRL)
  • Novo Nordisk

Related News

  • SC upholds Delhi HC ruling on National Book Trust’s status

    SC upholds Delhi HC ruling on National Book Trust’s status

  • Delhi HC grants 7-day custody parole to Al Falah University chairman to tend to ailing wife

    Delhi HC grants 7-day custody parole to Al Falah University chairman to tend to ailing wife

  • Kriti Sanon gets Delhi HC protection against AI-generated explicit images

    Kriti Sanon gets Delhi HC protection against AI-generated explicit images

  • Vinesh Phogat’s return to wrestling: HC seeks WFI decision on notices in two weeks

    Vinesh Phogat’s return to wrestling: HC seeks WFI decision on notices in two weeks

Latest News

  • KRMB cites jurisdictional constraints, asks Telangana and AP to follow approval process for new projects

    3 minutes ago
  • #OM review: Dhanush leads an explosive action-packed cinematic experience

    7 minutes ago
  • Palnadu Water Grid row: Notices to Telangana engineers raise questions over government’s response

    8 minutes ago
  • Mahela Jayawardene appointed Delhi Capitals’ Director of Cricket for WPL team

    8 minutes ago
  • India seeks balanced trade with Indonesia, highlights export opportunities

    18 minutes ago
  • India increases US Treasury holdings to $228.2 billion in September

    22 minutes ago
  • Nirmal: ED searches former MLA A Rekha Naik’s residence, rice mill

    23 minutes ago
  • Rajgopal Reddy hits back at Revanth Reddy, urges him to avoid arrogance and focus on governance

    30 minutes ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam

Telangana Today App